Baird raised its NRIX price target citing Roche partnership value and clinical progress in chronic lymphocytic leukemia trials.
Baird increased its price target for Nurix Therapeutics (NASDAQ:NRIX) to $33 from $26, maintaining an Outperform rating. The adjustment reflects the company’s partnership with Roche and advancements in its clinical programs.
Nurix recently reported updated Phase 1a/b trial data for bexobrutideg (NX-5948), showing an 83% objective response rate in relapsed/refractory chronic lymphocytic leukemia (CLL) patients. The therapy also demonstrated a median progression-free survival of 22.1 months and a favorable safety profile.
The results support a planned Phase 3 monotherapy program, reinforcing Nurix’s clinical-stage pipeline. Earlier-line cohorts showed response rates of 92.9% and 84.2%, further validating the drug’s potential.